Literature DB >> 16567960

Toll-like receptor signaling and atherosclerosis.

Kathrin S Michelsen1, Moshe Arditi.   

Abstract

PURPOSE OF REVIEW: Chronic inflammation and disordered lipid metabolism represent hallmarks of atherosclerosis. Considerable evidence has accumulated to suggest that innate immune defense mechanisms might interact with proinflammatory pathways and exacerbate or perhaps even initiate development of arterial plaques. Until recently the preponderance of such evidence has been indirectly emerging from clinical and epidemiologic studies, with some support from experimental animal models of atherosclerosis. RECENT
FINDINGS: Recent data now directly implicate signaling by toll-like receptor 4 and the common adaptor molecule MyD88 in the pathogenesis of atherosclerosis, establishing a key link between atherosclerosis and defense against both foreign pathogens and endogenously generated inflammatory ligands.
SUMMARY: Here we briefly review these and closely related studies, highlighting areas that should provide fertile ground for future studies aimed at a more comprehensive understanding of the interplay between innate immune defense mechanisms, atherosclerosis and related vascular disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567960     DOI: 10.1097/01.moh.0000219662.88409.7c

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  11 in total

1.  Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6.

Authors:  Zhongyang Lu; Yanchun Li; Junfei Jin; Xiaoming Zhang; Maria F Lopes-Virella; Yan Huang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-17       Impact factor: 8.311

Review 2.  New insights into insulin: The anti-inflammatory effect and its clinical relevance.

Authors:  Qiang Sun; Jia Li; Feng Gao
Journal:  World J Diabetes       Date:  2014-04-15

3.  Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression.

Authors:  Carlos H Serezani; Casey Lewis; Sonia Jancar; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

4.  Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice.

Authors:  Xiao-xing Wang; Xiao-xi Lv; Jia-ping Wang; Hui-min Yan; Zi-yan Wang; Han-zhi Liu; Xiao-ming Fu; Zhuo-wei Hu
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

5.  Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice.

Authors:  K R Coenen; M L Gruen; R S Lee-Young; M J Puglisi; D H Wasserman; A H Hasty
Journal:  Diabetologia       Date:  2008-12-04       Impact factor: 10.122

6.  mRNA-binding protein ZFP36 is expressed in atherosclerotic lesions and reduces inflammation in aortic endothelial cells.

Authors:  Huanchun Zhang; W Robert Taylor; Giji Joseph; Valentina Caracciolo; Donna M Gonzales; Neil Sidell; Emre Seli; Perry J Blackshear; Caleb B Kallen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-04       Impact factor: 8.311

7.  Toll-like receptors and myocardial inflammation.

Authors:  Yan Feng; Wei Chao
Journal:  Int J Inflam       Date:  2011-09-29

8.  A novel 72-kDa leukocyte-derived osteoglycin enhances the activation of toll-like receptor 4 and exacerbates cardiac inflammation during viral myocarditis.

Authors:  Marieke Rienks; Anna Papageorgiou; Kristiaan Wouters; Wouter Verhesen; Rick van Leeuwen; Paolo Carai; Georg Summer; Dirk Westermann; Stephane Heymans
Journal:  Cell Mol Life Sci       Date:  2016-11-23       Impact factor: 9.261

Review 9.  Macrophage Long Non-Coding RNAs in Pathogenesis of Cardiovascular Disease.

Authors:  Marcin Wysoczynski; Jae Kim; Joseph B Moore; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2020-07-11

Review 10.  Antigen-induced immunomodulation in the pathogenesis of atherosclerosis.

Authors:  Natalia Milioti; Alexandra Bermudez-Fajardo; Manuel L Penichet; Ernesto Oviedo-Orta
Journal:  Clin Dev Immunol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.